Bioactive Products
| A unique collection of 267 Inhibitor natural compounds | ||
| Catalog No: | Bb221 | Inhibitors Compound Library Screening Details |
| Size: | 1mg/well * 267 Compounds 2mg/well * 267 Compounds | |
| Cat. No. | Information |
| CFN90011 | Gefitinib Gefitinib (ZD-1839) is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively; it can reduce both cell proliferation and tumor growth of breast cancer cells expressing EGFR and/or HER2. Chronic Gefitinib treatment promotes ROS and mitochondrial dysfunction in lung cancer cells. Antioxidants may alleviate ROS-mediated resistance. |
| CFN98680 | 2,4,5-Trimethoxybenzaldehyde 2,4,5-Trimethoxybenzaldehyde (2,4,5-TMBA) has anti-adipogenic potential, is a natural cyclooxygenase II (COX-2) inhibitor, suppresses the differentiation of preadipocyts into adipocytes at the concentration of 0.5 mM. |
| CFN98681 | Genistein Genistein, a phytoestrogen found in soy products, is a highly specific inhibitor of protein tyrosine kinase (PTK) which blocks the mitogenic effect mediated by EGF on NIH-3T3 cells with IC50 of 12μM or by insulin with IC50 of 19 μM. Genistein has neuroprotective, antitumor effects, it modulates the expression of NF-κB and MAPK (p-38 and ERK1/2), thereby attenuating d-Galactosamine induced fulminant hepatic failure in Wistar rats. |
| CFN90018 | Ezetimibe Ezetimibe is known as a Niemann-Pick C1-Like 1 (NPC1L1) inhibitor and has been used as an agent for hypercholesterolemia, Ezetimibe and simvastatin are equipotent in lowering lipid levels in hypercholesterolemic patients with coexisting PCOS. Ezetimibe administration can improve glycemic control and increase glucagon like peptide-1 (GLP-1), an incretin hormone with anti-diabetic properties, a possible novel biological role of Ezetimibe in glycemic control to stimulate intestinal GLP-1 secretion via the MEK/ERK signaling pathway. |
| CFN90020 | Roflumilast Roflumilast is a phosphodiesterase 4 inhibitor that may improve lung function and reduce the frequency of exacerbations in patients with COPD. Roflumilast has anti-inflammatory and immunomodulatory potential,it will be useful in the treatment of chronic inflammatory disorders such as asthma and chronic obstructive pulmonary disease. Suppression of hematological and immunological markers of inflammation and enhanced apoptosis in animals treated with Roflumilast points to the possibility of a beneficial effect of Roflumilast in allergic inflammation. |
